Indications
Opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%.
Composition
- Active substance
- nivolumab, relatlimab
- International name (INN)
- relatlimab;nivolumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Opdualag
- Active substance
- nivolumab, relatlimab
- ATC code
- L01FY02
- Therapeutic area
- Melanoma
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG